First in class or best in class?
Which paths will ultimately lead to success with novel targeted therapies?
Ah this question often seems a perennial one to consider at AACR annual meetings – and this year is no different in this respect.
Personally, to me, it doesn’t really matter what you claim aspirationally based on preclinical or even early phase 1 dose escalation data because… a lot can happen between then and later registrational studies.
Think about it carefully – weak efficacy, wrong tumour selection or setting, adverse event profiles, even narrow therapeutic windows can all too soon interfere and play havoc like a wrecking ball with many a well intended clinical program, especially once you start looking at combination strategies!
No, it’s not as easy as it looks sometimes.
In our latest AACR Preview series, we take a look at a number of targeted agents in development, many aimed at novel targets at are not run-of-the mill…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the annual AACR meeting subscribers can log-in or you can click to gain access to BSB Premium Content.
Fall in Boston during the AACR-NCI-EORTC Triple meeting
After recent updates on targeting KRASG12C and HRAS, let’s not forget that there are plenty of other elements of the RAS pathway that can be considered, not least is upstream receptor kinases such as EGFR and sideways to SHP2.
What happens when those worlds collide?
Quite a bit it would seem.
If we want to seriously impact patient outcomes for the better then we need to explore rational combination approaches.
Here’s one way to do it…
Please note that this is an early target with not very many competitors, so there’s plenty that can happen here on multiple fronts!
To learn more from our oncology coverage on the RAS pathway and get a heads up on insights from our latest company interview, subscribers can log-in or you can click to gain access to BSB Premium Content.